See more : Linocraft Holdings Limited (8383.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Biofrontera AG (0DOL.L) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Biofrontera AG, a leading company in the Medical – Pharmaceuticals industry within the Healthcare sector.
- SEEK Limited (SKLTF) Income Statement Analysis – Financial Results
- Eucatex S.A. Indústria e Comércio (EUCA4.SA) Income Statement Analysis – Financial Results
- lastminute.com N.V. (LMN.SW) Income Statement Analysis – Financial Results
- BGIL FILMS & TECHNOLOGIES LTD. (BGIL.BO) Income Statement Analysis – Financial Results
- DBV Technologies S.A. (DBV.PA) Income Statement Analysis – Financial Results
Biofrontera AG (0DOL.L)
About Biofrontera AG
Biofrontera AG, a biopharmaceutical company, engages in the research, development, and marketing of dermatological products. Its products include Ameluz and BF-RhodoLED lamp for the treatment of mild and moderate actinic keratoses on the face and scalp, field cancerization, and fatal squamous cell carcinoma. The company also develops RhodoLED XL for the treatment of multiple interspersed lesions; Belixos, a modern active cosmetic product for irritated and sensitive skin; and Xepi for the treatment of antibiotic-resistant bacteria. It offers its products primarily in the United States, Europe, and Israel. The company has a collaboration and partnership agreement with Maruho Co., Ltd. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 32.25M | 25.74M | 28.79M | 30.35M | 31.27M | 21.11M | 12.03M | 6.13M | 4.14M | 3.10M | 3.11M | 3.43M |
| Cost of Revenue | 6.24M | 4.76M | 3.91M | 3.54M | 4.35M | 4.45M | 1.72M | 1.65M | 1.24M | 1.12M | 1.60M | 1.51M |
| Gross Profit | 26.01M | 20.98M | 24.87M | 26.81M | 26.92M | 16.66M | 10.31M | 4.48M | 2.90M | 1.98M | 1.51M | 1.92M |
| Gross Profit Ratio | 80.64% | 81.52% | 86.41% | 88.35% | 86.09% | 78.91% | 85.74% | 73.05% | 70.13% | 63.93% | 48.51% | 56.05% |
| Research & Development | 7.85M | 7.13M | 7.01M | 4.79M | 4.64M | 4.43M | 4.23M | 4.64M | 6.20M | 4.53M | 3.19M | 1.38M |
| General & Administrative | 6.11M | 5.91M | 11.32M | 9.15M | 15.24M | 12.96M | 3.10M | 2.85M | 2.76M | 3.24M | 2.43M | 4.09M |
| Selling & Marketing | 7.27M | 6.36M | 22.42M | 18.48M | 28.86M | 17.74M | 16.92M | 8.76M | 4.17M | 3.85M | 3.04M | 0.00 |
| SG&A | 13.38M | 12.26M | 33.75M | 27.63M | 44.10M | 30.71M | 20.02M | 11.62M | 6.93M | 7.09M | 5.46M | 4.09M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 21.22M | 64.03M | 14.52M | 36.84M | 29.11M | 34.16M | 25.32M | 13.85M | 12.95M | 11.74M | 8.35M | 4.56M |
| Cost & Expenses | 27.47M | 68.79M | 18.43M | 40.37M | 33.46M | 38.62M | 27.03M | 15.51M | 14.18M | 12.86M | 9.95M | 6.06M |
| Interest Income | 6.00K | 162.00K | 3.71M | 2.67M | 2.58M | 1.76M | 1.10M | 1.20M | 1.16M | 958.71K | 1.23M | 1.47M |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 213.00K | 187.00K | 280.00K | 277.00K | 2.04M | 754.00K | 760.00K | 822.00K | 799.00K | 796.58K | 733.63K | 632.43K |
| EBITDA | 5.00M | 1.78M | -15.60M | -5.33M | -19.78M | -17.72M | -13.17M | -10.96M | -9.43M | -8.85M | -6.40M | -2.92M |
| EBITDA Ratio | 15.49% | 6.91% | -54.20% | -17.57% | -63.26% | -83.97% | -109.56% | -178.74% | -227.94% | -285.91% | -205.62% | -85.10% |
| Operating Income | 4.78M | 1.59M | -15.88M | -5.61M | -21.82M | -18.48M | -13.93M | -11.78M | -10.23M | -9.65M | -7.14M | -3.55M |
| Operating Income Ratio | 14.83% | 6.18% | -55.17% | -18.49% | -69.77% | -87.54% | -115.88% | -192.15% | -247.25% | -311.64% | -229.17% | -103.54% |
| Total Other Income/Expenses | -6.91M | -44.80M | 71.02M | -7.09M | 17.04M | -791.00K | -2.17M | 1.20M | -972.00K | -1.07M | -928.88K | -550.16K |
| Income Before Tax | -2.13M | -43.21M | 35.68M | -12.70M | -4.78M | -19.27M | -16.10M | -10.58M | -11.20M | -10.72M | -8.07M | -4.10M |
| Income Before Tax Ratio | -6.60% | -167.88% | 123.96% | -41.84% | -15.28% | -91.29% | -133.90% | -172.58% | -270.73% | -346.33% | -259.00% | -119.57% |
| Income Tax Expense | 1.76M | 956.00K | 1.83M | 326.00K | 2.58M | 10.39M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 15.26K |
| Net Income | -369.00K | -44.17M | 38.32M | -13.02M | -7.36M | -8.88M | -16.10M | -10.58M | -11.20M | -10.72M | -8.07M | -4.12M |
| Net Income Ratio | -1.14% | -171.60% | 133.11% | -42.92% | -23.53% | -42.06% | -133.90% | -172.58% | -270.73% | -346.33% | -259.00% | -120.01% |
| EPS | -0.21 | -16.17 | 14.28 | -5.05 | -3.46 | -0.20 | -0.42 | -0.36 | -0.48 | -0.49 | -0.47 | -0.27 |
| EPS Diluted | -0.12 | -16.14 | 14.19 | -5.05 | -3.46 | -0.20 | -0.42 | -0.36 | -0.48 | -0.49 | -0.47 | -0.27 |
| Weighted Avg Shares Out | 1.76M | 2.73M | 2.68M | 2.58M | 2.13M | 43.70M | 38.08M | 29.74M | 23.16M | 21.76M | 17.34M | 15.00M |
| Weighted Avg Shares Out (Dil) | 3.04M | 2.74M | 2.70M | 2.58M | 2.13M | 43.70M | 38.08M | 29.74M | 23.16M | 21.76M | 17.34M | 15.00M |
Source: https://incomestatements.info
Category: Stock Reports